Salta al contenuto principale della pagina

MOLECULAR BASES OF THERAPY DESIGN

CODE 98814
ACADEMIC YEAR 2021/2022
CREDITS
  • 2.5 cfu during the 2nd year of 10598 MEDICAL-PHARMACEUTICAL BIOTECHNOLOGY(LM-9) - GENOVA
  • SCIENTIFIC DISCIPLINARY SECTOR MED/04
    LANGUAGE English
    TEACHING LOCATION
  • GENOVA
  • SEMESTER 2° Semester
    TEACHING MATERIALS AULAWEB

    OVERVIEW

    The course consists of 2.5 credits corresponding to 20 hour lessons.

    It is focused on the analysis of some important human pathologies that have been selected as representative diseases in which the study of molecular alterations and characteristics have led to the clarification of pathogenetic mechanims and to the development novel treatment strategies.

    AIMS AND CONTENT

    LEARNING OUTCOMES

    The course is aimed at exploring specific example pathologies as consequences of molecular alterations, with particular focus on tumors, and at illustrating novel methodological strategies to investigate disease pathogenetic mechanisms and identify new therapeutic targets.

    AIMS AND LEARNING OUTCOMES

    Aim of the course is: 1) to give information about selected pathologies including tumors, immunodeficiences and cystic fibrosis as examples of diseases related to molecular alterations, with particular focus on the pathogenetic mechanisms; 2) to elucidate different treatment strategies on the basis of the disease’s molecular characteristics.

    At the end of the course, students will have gained deeper knowledge of the molecular bases of representative human pathologies, and will be able to compare different therapeutic strategies by identifying pros and contras on the basis of the type of each approach and of the clinical and experimental outcomes.

    PREREQUISITES

    Good knowledge of cellular and molecular biology, general oncology, and immunology.

    TEACHING METHODS

    Oral presentations supported by Powerpoint slides.

    SYLLABUS/CONTENT

    General concepts of molecular pathology.

    CANCER

    Carcinogenesis as micro-evolutionary process. Clonal origin of tumors. Somatic mutations as the cause of tumors; genetic and epigenetic mutations. Genetic instability of tumor cells. Tumor progression: neoangiogenesis and metastases. Tumor aetiology: definition of initiators and promoters. The cancer genes: oncogenes and tumor suppressor genes. Anti-cancer therapies and multidrug resistance.

    Cancer stem cells

    Clonal evolution in cancerogenesis. The hierarchical model of tumor tissues: the cancer stem cell (CSC). Identification of CSC: phenotype, xenotransplantation, colony-spheroid formation, side population, and ALDH activity assays. Plasticity of the CSC model. Therapeutic strategies targeting CSC.

    Tumor microenvironment

    The cells of tumor microenvironment: cancer-associated fibroblasts (CAF), mesenchymal stem cells, tumor-associated macrophages (TAM) and their role in supporting tumor growth and metastasization. Caveolin-1 expression in CAF: protein function in health and disease. The “reverse Warburg effect”. Prognostic relevance of stromal Cav-1 expression in tumors.


     

    Chronic myeloid leukemia

    Molecular pathogeneis of CML: the Bcr-Abl gene. Course of disease. CML therapy: the revolution of tyrosine kinase inhibitors (TKI). Evaluation of therapy response: hematologic, cytogenetic, and molecular response. TKI resistance: Bcr-Abl mutations and leukemia stem cells (LSC). Survival pathways in LSC as new targets of CML therapies. The Programmed Cell Removal: “eat me” and “non eat me” signals; mechanisms of PCR evasion in tumor cells.

    New therapeutic strategies in acute myeloid lekemia: alloreactive NK cells and CAR-T cells

    Morphological and phenotypic classification of acute myeloid and lymphoid leukemias (AML, ALL). Regulation of Natural Killer (NK) cell function: activating and inhibitory receptors. Expression of NK receptor ligands on AML and ALL cells. Haploidentical hematopoietic stem cell transplantation (HSCT). NK cell allloreactivity: the KIR/HLA-class I mismatch. Correlation between NK cell alloreactivity and anti-leukemia effect: in vitro experience and clinical practice.

    Adoptive immunotherapy in allo-HSCT employing genetically engineered lymphocytes: the CAR-T cells. First, second and third generation CARs. Problems of CAR-T cell therapy: solution strategies. Use of suicide genes to block side effects of CAR-T cell therapies.


     

    PRIMARY IMMUNODEFICIENCES

    Classification of primary immunodeficiences (PIDs)

    Genetic alterations and pathogenetic mechanisms in PIDs: the examples of Adenosine deaminase (ADA) deficiency, X-linked Severe Combined Immune Deficiency (X-SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich Syndrome (WAS). The diverse therapeutic approaches for PIDs. Gene therapy for PIDs.


     

    CYSTIC FIBROSIS

    CFTR gene mutations and disease pathogenesis. Classes of CFTR mutations and their correlation with disease phenotype. Conventional therapies and novel therapeutic approaches for CF. The promising use of correctors and potentiators to cure CF.

    RECOMMENDED READING/BIBLIOGRAPHY

    Reference books:

    - Alberts et al. “Biologia molecolare della cellula”,  Zanichelli ;

    - Mendelsohn et al.  “The molecular basis of cancer”, Elsevier;

    - Robbins e Cotran, “Le basi patologiche delle malattie”, Elsevier.

    - Giacca M., “Terapia Genica”, Springer-Verlag Italia s.r.l

    TEACHERS AND EXAM BOARD

    Exam Board

    GRAZIA MARIA SPAGGIARI (President)

    CLAUDIA CANTONI

    LESSONS

    LESSONS START

    Lessons usually start in March.

    Class schedule

    All class schedules are posted on the EasyAcademy portal.

    EXAMS

    EXAM DESCRIPTION

    Oral exam.

    ASSESSMENT METHODS

    The student is asked to answer at least two questions about the course's topics, starting from a general view and then going into detail. Additional questions can be asked, in order to clarify the student's ability to evaluate and choose adequate solutions for the treatment of pathologies.

    Exam schedule

    Date Time Location Type Notes
    22/06/2022 09:30 GENOVA Orale